Medication info
Prena Capsules 75 mg (Pregabalin)

Prena Capsules 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Pharmgen Science Co., Ltd.
Appearance
Hard capsule with a reddish-brown upper part and a white lower part containing a white powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201704853 · Approved 2017.06.28 · Insurance code 670104130

Summary

Main use
Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as the total daily dose of pregabalin divided into 2 doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. Patients with renal impairment Creatinine clearance ≥60 (mL/min): Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance ≥30 -<60 (mL/min): Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance ≥15 -<30 (mL/min): Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance <15 (mL/min): Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Additional dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, an additional supplemental dose should be administered promptly after every 4 hours of hemodialysis. TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: An additional dose refers to a supplemental dose administered as a single dose. No dosage adjustment is required in patients with hepatic impairment. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age and adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Pharmgen Science Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures in patients with epilepsy. Additionally, it is effective in treating fibromyalgia. It is used to alleviate symptoms of various nerve-related disorders and reduce pain.

How to take

Adult dose

This medicine is administered orally as the total daily dose of pregabalin divided into 2 doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’) Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on the response and tolerability of the individual patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. Patients with renal impairment Creatinine clearance ≥60 (mL/min): Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance ≥30 -<60 (mL/min): Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance ≥15 -<30 (mL/min): Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance <15 (mL/min): Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Additional dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, an additional supplemental dose should be administered promptly after every 4 hours of hemodialysis. TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: An additional dose refers to a supplemental dose administered as a single dose. No dosage adjustment is required in patients with hepatic impairment. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age and adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This drug may increase the risk of suicidal thoughts or behaviors, so if there are any changes in mood or behavior, notify healthcare professionals immediately. Patients with hypersensitivity to this drug should not take it. Diabetic patients should be cautious as dose adjustments of blood sugar control medications may be necessary due to weight gain. If symptoms of angioedema occur, such as swelling of the face or around the mouth or difficulty breathing, discontinue the medication immediately. Elderly patients may experience increased dizziness or drowsiness which can elevate the risk of falls and accidents. Blurred vision or changes in eyesight may occur, and if these symptoms arise, discontinuation of the drug may improve the symptoms. When discontinuing this medication, withdrawal symptoms such as insomnia, headache, and anxiety may occur, and it should be gradually reduced in consultation with a healthcare professional. Patients with a history of drug abuse may be at higher risk of abusing this medication, so they should be carefully monitored. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should use this medication cautiously as there is a risk of congestive heart failure when taking it. Caution is needed when taken with opioid analgesics due to the increased risk of central nervous system depression. This drug may cause dizziness and drowsiness, so check for symptoms before driving or operating machinery. During early pregnancy, there may be a risk of fetal malformations; therefore, women who are pregnant or planning to become pregnant should consult with healthcare professionals and use effective contraception. Breastfeeding women should consider discontinuing the medication or breastfeeding as this drug can be transmitted through breast milk. In cases of overdose, symptoms such as confusion, drowsiness, depression, and seizures may occur; immediate medical attention is required.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • angioedema
  • facial swelling
  • swelling around the mouth
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
  • loss of consciousness
Show 186 more
  • confusion
  • mental disorders
  • blurred vision
  • visual changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • sadness
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • major congenital malformations
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • heightened sensitivity
  • elation
  • decreased libido
  • depersonalization
  • sexual dysesthesia
  • agitation
  • mood swings
  • emotional flattening
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • lack of inhibition
  • numbness
  • ataxia
  • movement coordination issues
  • balance disorders
  • amnesia
  • attention deficit
  • memory disorders
  • tremors
  • speech disorders
  • sensory disturbances
  • sensory loss
  • sedation
  • drowsiness syndrome
  • cognitive impairment
  • nystagmus
  • language disorders
  • clonic convulsions
  • decreased reflexes
  • movement abnormalities
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • bradycardia
  • tachyarrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • decreased oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urination disorders
  • incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased blood potassium
  • increased blood creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • shock
  • anaphylactic-like symptoms
  • Stevens-Johnson syndrome
  • erythema multiforme
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • state of confusion
  • agitation
  • restlessness
  • worsening of seizures
  • gastrointestinal disturbances
  • tinnitus
  • sleep disorders
  • skin diseases
  • increased BUN
  • blood in stool

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture, and kept in a cool place between 15 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Hard capsule with a reddish-brown upper part and a white lower part containing a white powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.